Denali Therapeutics Financial Statements (DNLI)
|
|
|
|
Report date
|
|
|
28.02.2022 |
27.02.2023 |
28.02.2024 |
27.02.2025 |
26.02.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
48.7 |
108.5 |
330.5 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-295.8 |
-340.7 |
-196.7 |
-487.3 |
-555.3 |
|
-547.1 |
|
EBITDA, bln rub |
? |
|
-287.2 |
-330.4 |
-180.0 |
-492.9 |
-497.6 |
|
-526.6 |
|
Net profit, bln rub |
? |
|
-290.6 |
-326.0 |
-145.2 |
-422.8 |
-512.5 |
|
-508.0 |
|
|
OCF, bln rub |
? |
|
-211.4 |
-244.7 |
-358.0 |
-347.7 |
-412.6 |
|
-412.3 |
|
CAPEX, bln rub |
? |
|
8.50 |
17.8 |
12.9 |
15.9 |
9.50 |
|
9.65 |
|
FCF, bln rub |
? |
|
-219.9 |
-262.5 |
-370.9 |
-363.6 |
-422.1 |
|
-419.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
344.4 |
449.2 |
527.2 |
487.3 |
544.2 |
|
544.3 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
11.2 |
|
2.87 |
|
R&D, bln rub |
|
|
265.4 |
358.7 |
423.9 |
396.4 |
418.8 |
|
406.4 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
1 404 |
1 460 |
1 154 |
1 374 |
1 145 |
|
1 266 |
|
Net Assets, bln rub |
? |
|
962.3 |
1 042 |
1 031 |
1 230 |
1 014 |
|
926.1 |
|
Debt, bln rub |
|
|
64.0 |
60.4 |
52.2 |
48.7 |
42.3 |
|
30.2 |
|
Cash, bln rub |
|
|
865.4 |
1 336 |
1 035 |
832.3 |
867.9 |
|
987.7 |
|
Net debt, bln rub |
|
|
-801.4 |
-1 276 |
-982.3 |
-783.6 |
-825.6 |
|
-957.5 |
|
|
Ordinary share price, rub |
|
|
44.6 |
27.8 |
21.5 |
20.4 |
16.5 |
|
19.6 |
|
Number of ordinary shares, mln |
|
|
121.5 |
125.5 |
137.4 |
164.5 |
175.5 |
|
186.6 |
|
|
Market cap, bln rub |
|
|
5 420 |
3 491 |
2 948 |
3 352 |
2 897 |
|
3 660 |
|
EV, bln rub |
? |
|
4 619 |
2 215 |
1 966 |
2 568 |
2 071 |
|
2 702 |
|
Book value, bln rub |
|
|
962 |
1 042 |
1 031 |
1 230 |
1 014 |
|
890 |
|
|
EPS, rub |
? |
|
-2.39 |
-2.60 |
-1.06 |
-2.57 |
-2.92 |
|
-2.72 |
|
FCF/share, rub |
|
|
-1.81 |
-2.09 |
-2.70 |
-2.21 |
-2.41 |
|
-2.25 |
|
BV/share, rub |
|
|
7.92 |
8.30 |
7.50 |
7.48 |
5.78 |
|
4.77 |
|
|
EBITDA margin, % |
? |
|
-590.1% |
-304.6% |
-54.4% |
|
|
|
|
|
Net margin, % |
? |
|
-597.2% |
-300.6% |
-43.9% |
|
|
|
|
|
FCF yield, % |
? |
|
-4.06% |
-7.52% |
-12.6% |
-10.8% |
-14.6% |
|
-11.5% |
|
ROE, % |
? |
|
-30.2% |
-31.3% |
-14.1% |
-34.4% |
-50.6% |
|
-54.9% |
|
ROA, % |
? |
|
-20.7% |
-22.3% |
-12.6% |
-30.8% |
-44.8% |
|
-40.1% |
|
|
P/E |
? |
|
-18.7 |
-10.7 |
-20.3 |
-7.93 |
-5.65 |
|
-7.20 |
|
P/FCF |
|
|
-24.6 |
-13.3 |
-7.95 |
-9.22 |
-6.86 |
|
-8.73 |
|
P/S |
? |
|
111.4 |
32.2 |
8.92 |
|
|
|
|
|
P/BV |
? |
|
5.63 |
3.35 |
2.86 |
2.73 |
2.86 |
|
4.11 |
|
EV/EBITDA |
? |
|
-16.1 |
-6.71 |
-10.9 |
-5.21 |
-4.16 |
|
-5.13 |
|
Debt/EBITDA |
|
|
2.79 |
3.86 |
5.46 |
1.59 |
1.66 |
|
1.82 |
|
|
R&D/CAPEX, % |
|
|
3 122% |
2 012% |
3 276% |
2 491% |
4 407% |
|
4 213% |
|
|
CAPEX/Revenue, % |
|
|
17.5% |
16.4% |
3.91% |
|
|
|
|
|
| Denali Therapeutics shareholders |
